银休特 2024年度报告

Washington, D.C. 20549 Form10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto Commission File Number001-33462 INSULET CORPORATION (Exact name of Registrant as specified in its charter) Securities registered pursuant to Section12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.Yes x No¨ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12months (or for such shorter period that the Registrant was required to file such reports) and (2)has been subject to such filing requirementsfor the past 90days.Yes x No¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit and post suchfiles).Yes x No¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See thedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filerxAccelerated filer¨ Non-accelerated filer¨ Smaller reporting company☐ Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issuedits audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements.¨ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received byany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).¨ Indicate by check mark whether the Registrant is a shell company (as defined in Rule12b-2 of the Act).Yes☐No☒ The aggregate market value of the common stock held by non-affiliates of the registrant computed by reference to the last reported sale price of the CommonStock as reported on The NASDAQ Global Market on June 30, 2024 was approximately $14.1billion. The number of shares of common stock outstanding as of February13, 2025 was70,226,104. DOCUMENTS INCORPORATED BY REFERENCE The registrant intends to file a proxy statement pursuant to Regulation14A within 120days of the end of the fiscal year ended December 31, 2024. Portions ofsuch proxy statement are incorporated by reference into PartIII of this Annual Report on Form10-K. TABLE OF CONTENTS PART I BusinessRisk FactorsUnresolved Staff CommentsCybersecurityPropertiesLegal ProceedingsMine Safety Disclosures PART II Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities30Reserved31Management’s Discussion and Analysis of Financial Condition and Results of Operations32Quantitative and Qualitative Disclosures About Market Risk40Financial Statements and Supplementary Data41Changes in and Disagreements with Accountants on Accounting and Financial Disclosure76Controls and Procedures76Other Information77 Item 5Item 6Item 7Item 7AItem 8Item 9Item 9AItem 9B PART III Directors, Executive Officers and Corporate Governance77Executive Compensation77Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters77Certain Relationships and Related Transactions, and Director Independence77Principal Accounting Fees and Services77 Item 10Item 11Item 12Item 13Item 14 PART IV Exhibits, Financial Statement SchedulesForm 10-K SummarySIGNATURES Item 15Item 16 Table of Contents PART I Item 1. Business Overview Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuousinsulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod5 Automated InsulinDelivery System (“Omnipod 5”), the Omnipod DASHInsulin Management System (“Omnipod DASH”), and the Omnipod